Human adenoviruses: Evading detection by cytotoxic T lymphocytes

Seminars in Virology

Volumn 8, Issue 5, 1998, Pages 387-397

  Blair, G Eric ^a   Hall, Kersten T ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Adenovirus E1A oncogene; E3 gene products; E3 19K; LMP; MHC class I molecules; Oncogenic transformation; TAP

Indexed keywords

CYTOKINE; GENE PRODUCT; GLYCOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR; VIRUS PROTEIN;

ADENOVIRUS; ADENOVIRUS 12; ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; ENDOPLASMIC RETICULUM; GENE REPRESSION; HOST CELL; IMMUNE SYSTEM; NONHUMAN; REVIEW; SEROTYPE; TRANSCRIPTION REGULATION; VIRUS INFECTION;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 12; RODENTIA;

EID: 0031804077     PISSN: 10445773     EISSN: None     Source Type: Journal    
DOI: 10.1006/smvy.1997.0140     Document Type: Article

References (88)

1. Doerfler W., Böhm P. The molecular repertoire of adenoviruses. Curr. Top. Microbiol. Immunol. 199:1995.
2. Moran E. DNA tumor virus transforming proteins and the cell cycle. Curr. Opin. Genes Dev. 3:1993;63-70.
3. Bayley S. T., Mymryk J. S. Adenovirus E1A proteins and transformation. Int. J. Oncol. 5:1994;425-444.
4. Graham F. L., Prevec L. Methods for construction of adenovirus vectors. Mol. Biotechnol. 3:1995;207-220.
5. Williams J., Williams M., Liu C., Telling G. Assessing the role of E1A in the differential oncogenicity of group A and group C human adenoviruses. Curr. Top. Microbiol. Immunol. 199:1995;149-175.
6. Boulanger P. A., Blair G. E. Expression and interactions of human adenovirus oncoproteins. Biochem. J. 275:1991;281-299.
7. Bhattacharya S., Eckner R., Grossman S., Oldread E., Arany Z., D'Andrea A., Livingston D. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-α Nature. 383:1996;344-347.
8. Raska K. Jr. Functional domains of adenovirus E1A oncogenes which control interactions with effectors of cellular immunity. Curr. Top. Microbiol. Immunol. 199:1995;131-148.
9. Kimelman D., Miller J. S., Porter D., Roberts B. E. E1A regions of the human adenoviruses and of the highly oncogenic simian adenovirus 7 are closely related. J. Virol. 53:1985;399-409.
10. Telling G. C., Williams J. Constructing chimeric type 12/type 5 adenovirus E1A genes and using them to identify an oncogenic determinant of adenovirus type 12. J. Virol. 68:1994;877-887.
11. Jelinek T., Pereira D. S., Graham F. L. Tumorigenicity of adenovirus-transformed rodent cells is influenced by at least two regions of adenovirus type 12 E1A. J. Virol. 68:1994;888-896.
12. Licht J. D., Grossel M. J., Figge J., Hansen U. M. Drosophilakruppel protein is a transcriptional repressor. Nature. 346:1990;76-79.
13. Elliott T. Transporter associated with antigen processing. Adv. Immunol. 65:1997;47-109.
14. Groettrup M., Soza A., Kuckelkorn U., Kloetzel P. M. Peptide antigen production by the proteosome: Complexity provides efficiency. Immunol. Today. 17:1996;429-435.
15. Kast W. M., Offringa R., Peters P. J., Voordonw A. C., Meloen R. H., van der Eb A. J., Melief C. J. M. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell. 59:1989;603-614.
16. Wold W. S. M., Gooding L. R. Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology. 184:1991;1-8.
17. Sester M., Burgert H.-G. Conserved cysteine residues within the E3/19K protein of adenovirus type 2 are essential for binding to major histocompatibility complex antigens. J. Virol. 68:1994;5423-5432.
18. Hermiston T. W., Tripp R. A., Sparer T., Gooding L. R., Wold W. S. Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J. Virol. 67:1993;5289-5298.
19. Paabo S., Nilsson T., Peterson P. A. Adenoviruses of subgenera B, C, D, and E modulate cell-surface expression of major histocompatibility complex class I antigens. Proc. Natl. Acad. Sci. USA. 83:1986;9665-9669.
20. Wold W. S. M., Hermiston T. W., Tollefson A. E. E3 transcription unit of adenovirus. Curr. Top. Microbiol. Immunol. 199:1995;237-274.
21. Burgert H.-G., Kvist S. An adenovirus type-2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell. 41:1985;987-997.
22. Burgert H.-G., Kvist S. The E3/19K protein of adenovirus type 2 binds to the domains of histocompatibility antigens. EMBO J. 6:1987;2019-2026.
23. Flomenberg P., Szmulewicz J., Gutierrez E., Lupatkin H. Role of the adenovirus E3-19K conserved region in binding major histocompatibility complex class I molecules. J. Virol. 66:1992;4778-4783.
24. Beier D. C., Cox J. H., Vining D. R., Cresswell P., Engelhard V. H. Association of human class I MHC alleles with the adenovirus E3/19K protein. J. Immunol. 152:1994;3862-3872.
25. kmice. J. Immunol. 146:1991;3977-3984.
26. Feuerbach D., Etteldorf S., Ebenau-Jehle C., Abastado J. P., Madden D., Burgert H. G. Identification of amino acids within the MHC class I molecule important for the interaction with adenovirus protein E3/19K. J. Immunol. 153:1994;1626-1636.
27. Rawle F. C., Tollefson A. E., Wold W. S. M., Gooding L. R. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K. J. Immunol. 143:1989;2031-2037.
28. Sprengel J., Schmitz B., Hens-Neitgel D., Zock C., Doerfler W. Nucleotide sequence of human adenovirus 12: comparative functional analysis. J. Virol. 68:1994;379-389.
29. Davison A. J., Telford E. A. R., Watson M. M., McBride K., Mautner V. The DNA sequence of adenovirus type 40. J. Mol. Biol. 234:1993;1308-1316.
30. Deryckere F., Burgert H.-G. Tumor necrosis factor α induces the adenovirus early 3 promoter by activation of NF-κB. J. Biol. Chem. 271:1996;30249-30255.
31. Gooding L. R., Elmore L. W., Tollefson A. E., Brady H. A., Wold W. S. A 14 700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell. 53:1988;341-346.
32. Gooding L. R., Ranheim T. S., Tollefson A. E. The 10 400 and 14 500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J. Virol. 65:1991;4114-4123.
33. Tufariello J. M., Cho S., Horwitz M. S. Adenovirus E3 14.7-kilodalton protein, an antagonist of tumor necrosis factor cytolysis, increases the virulence of vaccinia virus in severe combined immunodeficient mice. Proc. Natl. Acad. Sci. USA. 91:1994;10987-10991.
34. Tufariello J. M., Cho S., Horwitz M. S. The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model. J. Virol. 68:1994;453-462.
35. Gooding L. R., Sofola I. O., Tollefson A. E., Duerksen-Hughes P., Wold W. S. The adenovirus E3-14.7K protein is a general inhibitor of tumor necrosis factor-mediated cytolysis. J. Immunol. 145:1990;3080-3086.
36. Hoffman P., Yaffe M. B., Hoffman B. L., Yei S., Wold W. S., Carlin C. Characterization of the adenovirus E3 protein that down-regulates the epidermal growth factor receptor. J. Biol. Chem. 267:1992;13480-13487.
37. Krajcsi P., Dimitrov T., Hermiston T. W., Tollefson A. E., Ranheim T. S., Vande Pol S. B., Stephenson A. H., Wold W. S. The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumour necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J. Virol. 70:1996;4904-4913.
38. Dmitrov T., Krajsci P., Hermiston T. W., Tollefson A. E., Hannink M., Wold W. S. Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes. J. Virol. 71:1997;2830-2837.
39. Li Y., Kang J., Horwitz M. S. Interaction of an adenovirus 14.7-kilodalton protein inhibitor of tumour necrosis factor α cytolysis with a new member of the GTPase superfamily of signal transducers. J. Virol. 71:1997;1576-1582.
40. Sen G. C., Ransohoff R. M. Interferon-induced antiviral actions and their regulation. Adv. Virus Res. 42:1993;57-102.
41. Ghadge G. D., Swaminathan S., Katze M. G., Thimmapaya B. Binding of the adenovirus VAI RNA to the interferon induced 68-kDa protein kinase correlates with its function. Proc. Natl. Acad. Sci. USA. 88:1991;7140-7144.
42. Anderson K. P., Fennie E. H. Adenovirus early region 1A modulation of interferon antiviral activity. J. Virol. 61:1987;787-795.
43. Ackrill A. M., Foster G. R., Laxton C. D., Flavell D. M., Stark G. R., Kerr I. M. Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene. Nucleic Acids Res. 19:1991;4387-4393.
44. Gutch M. J., Reich N. C. Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc. Natl. Acad. Sci. USA. 88:1991;7913-7917.
45. Kalvakolanu D., Bandyopadhyay S., Harter M., Sen G. Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. Proc. Natl. Acad. Sci. USA. 88:1991;7459-7463.
46. Ihle J. N. STATs: Signal transduction and activation of transcription. Cell. 84:1996;331-334.
47. Routes J. M., Li H., Bayley S. T., Ryan S., Klemm D. J. Inhibition of IFN-stimulated gene expression and IFN induction of a cytolytic resistance to natural killer cell lysis correlate with E1A-p300. J. Immunol. 156:1996;1055-1061.
48. Leonard G. T., Sen G. C. Effects of adenovirus E1A protein on interferon signalling. Virology. 224:1996;25-33.
49. Janaswami P. M., Kalvakolanu D. V. R., Zhang Y., Sen G. C. Transcriptional repression of interleukin-6 gene by adenoviral E1A proteins. J. Biol. Chem. 267:1992;24886-24891.
50. Takeda T., Nakajima K., Kojima H., Hirano T. E1A repression of IL-6 induced gene activation by blocking the assembly of IL-6 response element binding complexes. J. Immunol. 153:1994;4573-4582.
51. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 8:1990;253-278.
52. Hirano T. The biology of interleukin-6. Chem. Immunol. 51:1992;153-156.
53. Kaplan J. M., Armentano D., Sparer T. E., Wynn S. G., Peterson P. A., Wadsworth S. C., Couture K. K., Pennington S. E., St George J. A., Smith A. E. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8:1997;45-56.
54. Ginsberg H. S., Moldawer L., Sehgal P., Redington M., Kilian P., Chanock R. M., Prince G. A. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA. 88:1991;1651-1655.
55. Ilan Y., Droguett G., Chowdhury N. R., Li Y., Sengupta K., Thummala N. R., Davidson A., Chowdhury J. R., Horwitz M. S. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune response and permits long-term gene expression. Proc. Natl. Acad. Sci. USA. 94:1997;2587-2592.
56. Elkon K. B., Liu C.-C., Gall J. G., Trevejo J., Marino M. W., Abrahamsen K. A., Song X., Zhou J.-L., Old L. J., Crystal R. G., Falck-Pedersen E. Tumor necrosis factor α plays a central role in immune-mediated clearance of adenoviral vectors. Proc. Natl. Acad. Sci. USA. 94:1997;9814-9819.
57. Poller W., Schneider-Rasp S., Liebert U., Merklein F., Thalheimer P., Haack A., Schwaab R., Schmitt C., Brackmann H. H. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Ther. 3:1996;521-530.
58. Schowalter D. B., Tubb J. C., Liu M., Wilson C. B., Kay M. A. Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro but does not prolong transgene expressionin vivo. Gene Ther. 4:1997;351-360.
59. Blair G. E., Proffitt J. L., Blair Zajdel M. E. Modulation of f MHC class I antigen expression in adenovirus infection and transformation. Modulation of MHC Antigen Expression and Disease. 1995;Cambridge Univ. Press, Cambridge. p. 192-232.
60. Yewdell J. W., Bennink J. R., Eager K. B., Ricciardi R. P. CTL recognition of adenovirus-transformed cells infected with influenza virus: Lysis by anti-influenza CTLs parallels adenovirus 12-induced suppression of class I MHC molecules. Virology. 162:1988;236-238.
61. Hayashi H., Tanaka K., Jay F., Khoury G., Jay G. Modulation of the tumorigenicity of human adenovirus-12-transformed cells by interferon. Cell. 43:1985;263-267.
62. Tanaka K., Isselbacher K. J., Khoury G., Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science. 228:1985;26-30.
63. Ge R., Liu X., Ricciardi R. P. E1A oncogene of adenovirus 12 mediates trans-repression of MHC class I transcription in Ad5/Ad12 somatic hybrid transformed cells. Virology. 203:1994;389-392.
64. Ackrill A. M., Blair G. E. Regulation of major histocompatibility class I gene expression at the level of transcription in highly oncogenic adenovirus transformed rat cells. Oncogene. 3:1988;483-487.
65. Friedman D. J., Ricciardi R. P. Adenovirus type 12 E1A represses accumulation of MHC class I mRNAs at the level of transcription. Virology. 165:1988;303-305.
66. Liu X., Ge R., Westmoreland S., Cooney A. J., Tsai S. Y., Tsai M.-J., Ricciardi R. P. Negative regulation by the R2 element of the MHC class I enhancer in adenovirus 12 transformed cells correlates with high levels of COUP-TF binding. Oncogene. 9:1994;2183-2190.
67. Baldwin A. S. The NF-κB and I-κB proteins: New discoveries and insights. Annu. Rev. Immunol. 14:1996;649-681.
68. Ackrill A. M., Blair G. E. Nuclear proteins binding to an enhancer element of the major histocompatibility class I promoter: Differences between highly oncogenic and nononcogenic adenovirus-transformed rat cells. Virology. 172:1989;643-646.
69. Ge R., Kralli A., Weinmann R., Ricciardi R. P. Down-regulation of the major histocompatibility class I enhancer in adenovirus 12-transformed cells is accompanied by an increase in factor binding. J. Virol. 66:1992;6969-6978.
70. Meijer I., Boot A. J. M., Mahibin G., Zantema A., van der Eb A. J. Reduced binding activity of the transcription factor NF-κB accounts for the MHC class I repression in adenovirus 12 E1-transformed cells. Cell. Immunol. 145:1992;56-65.
71. Kralli A., Ge R., Graeven U., Ricciardi R. P., Weinmann R. Negative regulation of the major histocompatibility class I enhancer in adenovirus type 12-transformed cells via a retinoic acid response element. J. Virol. 66:1992;6979-6988.
72. Schmitz M. L., Indorf A., Limbourg F. P., Städtler H., Traeckner E. B.-M., Baeurle P. A. The dual effect of adenovirus type 5 E1A 13S protein on NF-κB activation is antagonized by E1B 19K. Mol. Cell. Biol. 15:1996;4052-4063.
73. Schouten G. J., van der Eb, Zantema A. Down-regulation of MHC class I expression due to interference with p105- NF-κB1 processing by Ad12 E1A. EMBO J. 14:1995;1498-1507.
74. Liu X., Ge R., Ricciardi R. P. Evidence for the involvement of a nuclear NF-κB inhibitor in global down-regulation of the major histocompatibility class I enhancer in adenovirus type 12-transformed cells. Mol. Cell. Biol. 16:1996;398-404.
75. Kushner D. B., Pereira D. S., Liu X., Graham F. L., Ricciardi R. P. The first exon of Ad12 E1A excluding the transactivation domain mediates differential binding of COUP-TF and NF-κB to the MHC class I enhancer in transformed cells. Oncogene. 12:1996;143-151.
76. Proffitt J. L., Sharma E., Blair G. E. Adenovirus 12-mediated down-regulation of the major histocompatibility (MHC) class I promoter: Identification of a negative regulatory element responsive to Ad12 E1A. Nucleic Acids Res. 22:1994;4779-4788.
77. bclass I antigen by adenovirus 12 E1A is mediated by a CAA repeated element. J. Biol. Chem. 268:1993;27258-27268.
78. bclass I gene. J. Biol. Chem. 270:1995;2327-2336.
79. Peltenburg L. T. C., Schrier P. I. Transcriptional suppression of HLA-B expression by c-myc is mediated through the core promoter elements. Immunogenetics. 40:1994;54-61.
80. Rotem-Yehudar R., Winograd S., Sela S., Coligan J. E., Ehrlich R. Down-regulation of peptide transporter genes in cell lines transformed with the highly oncogenic adenovirus 12. J. Exp. Med. 180:1994;477-488.
81. Rotem-Yehudar R., Groettrup M., Soza A., Kloetzel P. M., Ehrlich R. LMP-associated proteolytic activities and TAP-dependent peptide transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J. Exp. Med. 183:1996;499-514.
82. Proffitt J. A., Blair G. E. The MHC-encoded TAP1/LMP2 bidirectional promoter is down-regulated in highly oncogenic adenovirus type 12 transformed cells. FEBS Lett. 400:1997;141-144.
83. Eyler Y. L., Siwarski D. F., Huppi K. E., Lewis A. M. Down-regulation of Waf1, C2, C3 and major histocompatibility class I loci within an 18cM region of chromosome 17 in adenovirus-transformed mouse cells. Mol. Carcinog. 18:1997;213-220.
84. Huvent I., Cousin C., Kiss A., Bernard C., D'Halluin J. C. Susceptibility to natural killer cells and down-regulation of MHC class I expression in adenovirus 12 transformed cells are regulated by different E1A domains. Virus Res. 45:1996;123-134.
85. Meijer I., Jochemsen A. G., de Wit C. M., Bos J. L., Morello D., van der Eb A. J. Adenovirus type 12 E1A down-regulates expression of a transgene under control of a major histocompatibility complex class I promoter: evidence for transcriptional control. J. Virol. 63:1989;4039-4042.
86. Efrat S., Fejer G., Brownlee M., Horwitz M. Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes. Proc. Natl. Acad. Sci. USA. 92:1995;6947-6951.
87. Von Herrath M. G., Efrat S., Oldstone M. B. A., Horwitz M. S. Expression of adenoviral E3 transgenes in β cells prevents autoimmune diabetes. Proc. Natl. Acad. Sci. USA. 94:1997;9808-9813.
88. Garrido F., Cabrera T., Lopez Nevot M. A., Ruiz Cabello F. HLA class I antigens in human tumors. Adv. Cancer Res. 67:1995;155-195.